ArticleThe Journal of experimental medicine2004
Inflammation-associated cell cycle-independent block of apoptosis by survivin in terminally differentiated neutrophils.
Article in The Journal of experimental medicine, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 201 citations in OpenAlex.
- Neutrophil Heterogeneity in Airway Inflammatory Diseases.Inflammation · 2025Review
- Dual Nature of Neutrophil Extracellular Traps (NETs)-From Cancer's Ally to Therapeutic Target.Cells · 2025Review
- Preliminary evidence of immune infiltration and neutrophil degranulation in peripheral blood of non-obese OSA patients related to cognitive decline.Scientific reports · 2025Article
- Interaction of SMAC with a survivin-derived peptide alters essential cancer hallmarks: Tumor growth, inflammation, and immunosuppression.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Elevated CD169 expressing monocyte/macrophage promotes systemic inflammation and disease progression in cirrhosis.Clinical and experimental medicine · 2024Article
- Article
- NETworking with cancer: The bidirectional interplay between cancer and neutrophil extracellular traps.Cancer cell · 2023Review
- Putative Role of Neutrophil Extracellular Trap Formation in Chronic Myeloproliferative Neoplasms.International journal of molecular sciences · 2023Review
- Neutrophil extracellular traps in the pathology of cancer and other inflammatory diseases.Physiological reviews · 2023Review
- Delayed neutrophil apoptosis may enhance NET formation in ARDS.Respiratory research · 2022Article
- Generation of resolving memory neutrophils through pharmacological training with 4-PBA or genetic deletion of TRAM.Cell death & disease · 2022Article
- Dysregulation of Survivin-Targeting microRNAs in Autoimmune Diseases: New Perspectives for Novel Therapies.Frontiers in immunology · 2022Review
- Neutrophil extracellular traps and complications of liver transplantation.Frontiers in immunology · 2022Review
- The Behaviour of Serum Survivin in Patients With Lupus Nephritis.Biomarker insights · 2022Article
- Article
- Shift of Neutrophils From Blood to Bone Marrow Upon Extensive Experimental Trauma Surgery.Frontiers in immunology · 2022Article
- Article
- Survivin and caspases serum protein levels and survivin variants mRNA expression in sepsis.Scientific reports · 2021Observational
- Neutrophil Homeostasis and Emergency Granulopoiesis: The Example of Systemic Juvenile Idiopathic Arthritis.Frontiers in immunology · 2021Review
- An exploratory analysis of extracellular vesicle-associated and soluble cytokines in cancer-related fatigue in men with prostate cancer.Brain, behavior, & immunity - health · 2020Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Survivin has received great attention due to its expression in many human tumors and its potential as a therapeutic target in cancer. Survivin expression has been described to be cell cycle-dependent and restricted to the G2-M checkpoint, where it inhibits apoptosis in proliferating cells. In agreement with this current view, we found that survivin expression was high in immature neutrophils, which proliferate during differentiation. In contrast with immature cells, mature neutrophils contained only little or no survivin protein. Strikingly, these cells reexpressed survivin upon granulocyte/macrophage colony-stimulating factor (CSF) or granulocyte CSF stimulation in vitro and under inflammatory conditions in vivo. Moreover, survivin-deficient mature neutrophils were unable to increase their lifespan after survival factor exposure. Together, our findings demonstrate the following: (a) overexpression of survivin occurs in primary, even terminally differentiated cells and is not restricted to proliferating cells; and (b) survivin acts as an inhibitor of apoptosis protein in a cell cycle-independent manner. Therefore, survivin plays distinct and independent roles in the maintenance of the G2-M checkpoint and in apoptosis control, and its overexpression is not restricted to proliferating cells. These data provide new insights into the regulation and function of survivin and have important implications for the pathogenesis, diagnosis, and treatment of inflammatory diseases and cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.